Mohammad Abu-Rub
Neurology · Charlotte, NCNPI 1154689255
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Amgen at 25.8% of the total. Reporting peaked in 2022 at $702 and has fallen 80.8% since, to $135 in 2025.
Across 45 payments — averaging $29.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$341
- Avanir Pharmaceuticals, Inc.$184
- AbbVie$170
- TG Therapeutics, Inc.$154
- CSL Behring$122
- Takeda Pharmaceuticals U.S.A., Inc.$102
- plus $249 from 7 others
Across 4 payments — averaging $1081.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$4K
- Hoffmann-la Roche Limited$358
What the payments were for
- Food & beverage$1,321100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 13 | $341 |
| Avanir Pharmaceuticals, Inc. | 8 | $184 |
| AbbVie(2 entities) | 7 | $170 |
| TG Therapeutics, Inc. | 2 | $154 |
| CSL Behring | 1 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $102 |
| Genentech USA, Inc. | 4 | $87 |
| AstraZeneca | 1 | $57 |
| Argenx US, Inc. | 1 | $29 |
| Biogen | 1 | $22 |
| UCB, Inc. | 1 | $20 |
| Genentech, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,321 in reported general payments places this provider in the 55th percentile of 566 neurology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 18 | $24,250 |
| Emgality PenGalcanezumab-Gnlm | 15 | $10,867 |
| Gabapentin | 59 | $1,589 |
| Pregabalin | 21 | $920 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 27 | $915 |
| Memantine Hcl | 23 | $582 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 25 | $516 |
| Duloxetine Hcl | 22 | $505 |
| RizatriptanRizatriptan Benzoate | 12 | $430 |
| Donepezil Hcl | 39 | $331 |
| Primidone | 24 | $285 |
| Levetiracetam | 11 | $283 |
| Promethazine Hcl | 11 | $166 |
| Trazodone Hcl | 14 | $108 |
| Clonazepam | 11 | $107 |
Paid to pharmacies, not to this prescriber.
Other neurology in Charlotte
- Jill ConwayCharlotte$1M
- Matthew CarraroCharlotte$695K
- Megan DonnellyCharlotte$601K
- Sanjay IyerCharlotte$581K
- Urvi DesaiCharlotte$262K
- Danielle Englert DoggettCharlotte$215K
- Robert WigginsCharlotte$138K
- Ardith CourtneyCharlotte$120K
- Joseph ChipmanCharlotte$118K
- Kurt WashburnCharlotte$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.